The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

Trevi Therapeutics’ stock value has shot up more than 53% after its investigational therapy Haduvio (nalbuphine hydrochloride) reduced the frequency of coughing fits by 57% compared to placebo ...